Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ATOSSA THERAPEUTICS, INC. (ATOS)

Atossa Therapeutics executes CVR agreement giving holders 25% of future priority voucher proceeds

Neutral Impact 3 of 5 shareholder Written later

Atossa Therapeutics entered into a Stapled Contingent Value Rights Agreement with VStock Transfer, LLC, and its board declared one stapled CVR for each common share outstanding at the close of business on October 19, 2026. Holders would receive a share of 25% of net proceeds from the sale or deemed monetization of the company's first qualifying FDA priority review voucher, capped at $50 million, but no voucher has been awarded and payment is not assured.

Key points

  • Record date is October 19, 2026; one stapled CVR per share, with shares issued later also carrying a CVR until detachment or expiration.
  • Aggregate CVR payments equal 25% of net proceeds from the first qualifying voucher, capped at $50 million, for vouchers awarded on or before December 31, 2036.
  • No priority review voucher has been awarded, and no marketing application for (Z)-endoxifen has been submitted; the company is not required to pursue approval or sell a voucher.
  • CVRs do not carry voting or dividend rights and will not trade separately while attached to the shares.

The filing

CompanyATOSSA THERAPEUTICS, INC. (ATOS)
Form8-K, current report
Filed with the SECOct 9, 2026, 8:15 AM ET
Accession number0001193125-26-418560

Items reported: 1.01 Material Definitive Agreement3.03 Change to Shareholder Rights8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.